Creso Pharma is a step closer to unlocking Australian market
Creso Pharma Limited (ASX:CPH, FRA: 1X8) has today obtained an exclusive Heads of Agreement (HOA) with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd.
The agreement could see Creso Pharma capitalise on opportunities to supply cannabidiol (CBD) products to the Australian market.
Martin and Pleasance (M&P) provides an extensive range of natural remedies and medicines to consumers, with a particular focus on pioneering new and emerging products.
Established over 150 years ago and 100% Australian owned, M&P has a strong Australian presence; directly servicing over 4,000 Pharmacies across Australia and New Zealand, in addition to established online sales channels and additional distribution partners in the UK and Canada.
Under the non-binding agreement agreement, the parties have confirmed their intention to negotiate and enter into a formal binding and exclusive Collaborative Agreement on or before 30 April 2021, under which Creso Pharma will look to manufacture a range of CBD products in Switzerland, which would be sold under new and existing Martin and Pleasance brands in Australia.
Creso Pharma has earmarked four products from its proprietary nutraceutical range in lozenge and tea form, which are all manufactured in a GMP certified compliant facility.
This news follows an interim decision from the Therapeutic Goods Administration (“TGA”) to down schedule CBD products to schedule 3 medicines in Australia, which would allow adults ages 18 or over to purchase CBD products over-the-counter through pharmacies without the requirement of a prescription.
The TGA’s final decision is expected to be delivered in the coming weeks, and entry into the proposed Collaborative Agreement with M&P remains subject to a positive outcome from the decision.
The agreement sets a framework for Creso Pharma to respond quickly to a favourable TGA decision and directly access the Australian CBD market, which has a projected value of ~$200m.
The last few weeks have been kind to Creso, as it has received several purchase orders, the most recent from the Province of Ontario in Canada.
Promising regulatory changes from the United States, European Union and the United Nations have also accentuated the potential medical properties of cannabis and subsequent commercial value, which has had a favourable impact on CPH's share price.
CPH recently saw share price gains of over 1300%, achieving a 12 month high of 46 cents earlier this week, up from 3.1 cents a fortnight ago.
Creso Pharma Non-Executive Chairman, Adam Blumenthal explained: “The planned down scheduling of CBD products in Australia paves the way for Creso to introduce its unique and sophisticated range of GMP products and capitalise on what is expected to be a large market opportunity.
“Martin & Pleasance have a leading reputation in Australia, as well as established sales channels which would directly benefit Creso Pharma. We are excited to jointly develop this opportunity with them and expect our products to be very well received by consumers.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.